Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: A systematic review of the literature

Atherosclerosis

Volumn 225, Issue 1, 2012, Pages 11-21

  Gregson, John ^a   Stirnadel Farrant, Heide A ^b   Doobaree, Indraraj Umesh ^b   Koro, Carol ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

1 Alkyl acetylglycerophosphocholine Esterase; EC 3.1.1.47; Lipoprotein associated phospholipase A2; Platelet activating factor acetylhydrolase

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2;

AFRICAN AMERICAN; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; HISPANIC; HUMAN; KIDNEY DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AFRICAN AMERICANS; ANIMALS; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INFLAMMATION; LIPIDS; MALE; RISK FACTORS; SEX FACTORS;

EID: 84867852397     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.06.020     Document Type: Review

References (100)

1. Kolodgie F., Burke A., Skorija K., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2523-2529.
2. Lp-PLA2 Studies Collaboration, Thompson A., Gao P., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
3. White H., Held C., Stewart R., et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque by initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010, 160:655-661.
4. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 Activity, and 10-year cardiovascular outcomes: prospective results from the bruneck study. Arterioscler Thromb Vasc Biol 2007, 27:1788-1795.
5. Karabina S., Elisaf M., Bairaktari E., Tzallas C., Siamopoulos K., Tselepis A. Increased activity of platelet-activating factor acetylhydrolase in low- density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997, 27:595-602.
6. Macphee C., Moores K., Boyd H., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999, 338:479-487.
7. Oehlert G.W. A note on the delta method. Am Statist 1992, 46:27-29.
8. O'Donoghue M., Morrow D.A., Sabatine M.S., et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006, 113:1745-1752.
9. Robins S.J., Collins D., Nelson J.J., Bloomfield H.E., Asztalos B.F. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2008, 28:1172-1178.
10. Berger J.S., Ballantyne C.M., Davidson M.H., et al. Peripheral artery disease, biomarkers, and darapladib. Am Heart J 2011, 161:972-978.
11. Mohler E.R., Ballantyne C.M., Davidson M.H., et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008, 51:1632-1641.
12. Hoffmann M.M., Winkler K., Renner W., et al. Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost 2009, 7:41-48.
13. Winkler K., Hoffmann M.M., Winkelmann B.R., et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem 2007, 53:1440-1447.
14. Casas J.P., Ninio E., Panayiotou A., et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010, 121:2284-2293.
15. Drenos F., Talmud P.J., Casas J.P., et al. Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Genet 2009, 18:2305-2316.
16. Blankenberg S., Stengel D., Rupprecht H.J., et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003, 44:1381-1386.
17. Ninio E., Tregouet D., Carrier J.L., et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 2004, 13:1341-1351.
18. Hatoum I.J., Hu F.B., Nelson J.J., Rimm E.B. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes 2010, 59:1239-1243.
19. Hatoum I.J., Nelson J.J., Cook N.R., Hu F.B., Rimm E.B. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr 2010, 91:786-793.
20. Corsetti J.P., Rainwater D.L., Moss A.J., Zareba W., Sparks C.E. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006, 52:1331-1338.
21. Wootton P.T.E., Stephens J.W., Hurel S.J., et al. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. Atherosclerosis 2006, 189:149-156.
22. Miller R.G., Costacou T., Orchard T.J. Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria. Diab Vasc Dis Res 2010, 7:47-55.
23. Kardys I., Oei H., Hofman A., Oudkerk M., Witteman J. Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis 2007, 191:377-383.
24. Oei H.H.S., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570-575.
25. Rana J.S., Cote M., Despres J.P., et al. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. Heart (British Cardiac Society) 2009, 95:1682-1687.
26. Yamada Y., Ichihara S., Fujimura T., Yokota M. Identification of the G994-> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998, 47:177-181.
27. Kim J.Y., Hyun Y.J., Jang Y., et al. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr 2008, 88:630-637.
28. Serban M., Tanaseanu C., Kosaka T., et al. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus. J Cell Mol Med 2002, 6:643-647.
29. Sonoki K., Iwase M., Sasaki N., et al. Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009, 86:117-123.
30. Gong H.P., Du Y.M., Zhong L.N., et al. Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis 2011, 10:13.
31. Denizot Y., Aupetit C., Bridoux F., Alphonse J.C., Cogné M., Aldigier J.C. Deregulated platelet-activating factor levels and acetylhydrolase activity in patients with idiopathic IgA nephropathy. Nephrol Dial Transplant 2000, 15:1344-1347.
32. Rosso L.G., Benítez M.B., Fornari M.C., et al. Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome. Atherosclerosis 2008, 199:415-423.
33. Hasselwander O., McMaster D., Fogarty D.G., Maxwell A.P., Nicholls D.P., Young I.S. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998, 44:179-181.
34. Papavasiliou E., Gouva C., Siamopoulos K., Tselepis A. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transplant 2006, 21:1270-1277.
35. Hou L., Chen S., Yu H., et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009, 125:11-20.
36. Jang Y., Kim O.Y., Koh S.J., et al. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 2006, 91:3521-3527.
37. Satoh K., Imaizumi T., Kawamura Y., Yoshida H., Takamatsu S., Takamatsu M. Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. Prostaglandins 1989, 37:673-682.
38. Gomes M.B., Cobas R.A., Nunes E., et al. Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2009, 85:61-68.
39. Mitsutake R., Ichiro Miura S., Zhang B., Saku K. HDL-associated factors provide additional prognostic information for coronary artery disease as determined by multi-detector row computed tomography. Int J Cardiol 2010, 143:72-78.
40. Juretic D., Flegar-Mestric Z., Petlevski R., Taduanovic M., Baricic M., Kosaka T. Serum platelet-activating factor acetylhydrolase activity in long-term hemodialysis patients. Period Biol 2005, 107:221-224.
41. Wegner M., Araszkiewicz A., Pioruńska-Mikołajczak A., Zozulińska-Ziółkiewicz D., Wierusz-Wysocka B., Pioruńska-Stolzmann M. The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clin Biochem 2009, 42:1621-1627.
42. Detopoulou P., Nomikos T., Fragopoulou E., et al. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem 2009, 42:44-49.
43. Detopoulou P., Nomikos T., Fragopoulou E., et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Lipids Health Dis 2009, 8:19.
44. Shohet R.V., Anwar A., Johnston J.M., Cohen J.C. Plasma platelet-activating factor acetylhydrolase activity is not associated with premature coronary atherosclerosis. Am J Cardiol 1999, 83:109-111. A8-9.
45. Li S., Stuart L., Zhang Y., Meduri G.U., Umberger R., Yates C.R. Inter-individual variability of plasma PAF-acetylhydrolase activity in ARDS patients and PAFAH genotype. J Clin Pharm Ther 2009, 34:447-455.
46. Sabatine M.S., Morrow D.A., O'Donoghue M., et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007, 27:2463-2469.
47. Oldgren J., James S.K., Siegbahn A., Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007, 28:699-704.
48. Albert M.A., Glynn R.J., Wolfert R.L., Ridker P.M. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 2005, 182:193-198.
49. Mochari H., Grbic J.T., Mosca L. Usefulness of self-reported periodontal disease to identify individuals with elevated inflammatory markers at risk of cardiovascular disease. Am J Cardiol 2008, 102:1509-1513.
50. Davidson M.H., Rooney M.W., Drucker J., et al. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther 2009, 31:2824-2838.
51. Pedersen M.W., Koenig W., Christensen J.H., Schmidt E.B. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr 2009, 48:1-5.
52. Tsai A.K., Steffen B.T., Ordovas J.M., et al. Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants. Transl Res 2011, 158:99-105.
53. May H.T., Horne B.D., Anderson J.L., et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 2006, 152:997-1003.
54. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343:1148-1155.
55. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
56. Koenig W., Meisinger C., Baumert J., Khuseyinova N., Lowel H. Systemic low-grade inflammation and risk of coronary heart disease: results from the MONICA/KORA Augsburg cohort studies. Gesundheitswesen 2005, 67:S62-S67.
57. Brilakis E.S., McConnell J.P., Lennon R.J., Elesber A.A., Meyer J.G., Berger P.B. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005, 26:137-144.
58. Elkind M., Tai W., Coates K., Paik M., Sacco R. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009, 27:42-50.
59. Elkind M.S.V., Leon V., Moon Y.P., Paik M.C., Sacco R.L. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke 2009, 40:3233-3237.
60. Wright C.B., Moon Y., Paik M.C., et al. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke 2009, 40:3466-3471.
61. Gerber Y., McConnell J.P., Jaffe A.S., Weston S.A., Killian J.M., Roger V.L. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006, 26:2517-2522.
62. Arain F.A., Khaleghi M., Bailey K.R., Lahr B.D., Rooke T.W., Kullo I.J. White blood cell count predicts all-cause mortality in patients with suspected peripheral arterial disease. Am J Med 2009, 122:874.e1-874.e7.
63. Daniels L.B., Laughlin G.A., Sarno M.J., Bettencourt R., Wolfert R.L., Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008, 51:913-919.
64. Wassertheil-Smoller S., Kooperberg C., McGinn A.P., et al. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 2008, 51:1115-1122.
65. Khuseyinova N., Imhof A., Rothenbacher D., et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005, 182:181-188.
66. Kujiraoka T., Iwasaki T., Ishihara M., et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 2003, 44:2006-2014.
67. Santos S., Rooke T.W., Bailey K.R., McConnell J.P., Kullo I.J. Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index. Vasc Med 2004, 9:171-176.
68. El-Saed A., Sekikawa A., Zaky R.W., et al. Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men. J Epidemiol 2007, 17:179-185.
69. Dullaart R.P.F., Constantinides A., Perton F.G., et al. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile. J Clin Endocrinol Metab 2011, 96:1077-1084.
70. Constantinides A., van Pelt L.J., van Leeuwen J.J.J., et al. Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes. Eur J Clin Invest 2011, 41:820-827.
71. Noto H., Chitkara P., Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications 2006, 20:343-348.
72. Heart Protection Study Collaborative Group Lipoprotein-associated phospholipase A? Activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 2010, 268:348-358.
73. Caslake M.J., Packard C.J., Robertson M., et al. Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis 2010, 210:28-34.
74. Shepherd J., Blauw G.J., Murphy M.B., et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999, 84:1192-1197.
75. Karalis I.K., Bergheanu S.C., Wolterbeek R., et al. Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Curr Med Res Opin 2010, 26:2301-2313.
76. Suchindran S., Rivedal D., Guyton J.R., et al. Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet 2010, 6:e1000928.
77. Schnabel R., Dupuis J., Larson M., et al. Clinical and genetic factors associated with lipoprotein-associated phospholipase A(2) in the Framingham Heart Study. Atherosclerosis 2009.
78. Persson M., Hedblad B., Nelson J.J., Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007, 27:1411-1416.
79. Furberg C., Nelson J., Solomon C., Cushman M., Jenny N., Psaty B. Distribution and correlates of lipoprotein-associated phospholipase A 2 in an elderly cohort: the cardiovascular health study. J Am Geriatr Soc 2008, 56:792-799.
80. Nelson T.L., Kamineni A., Psaty B., et al. Lipoprotein-associated phospholipase A(2) and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study. Diabetologia 2011, 54:329-333.
81. Olson N., O'Meara E.S., Jenny N.S., et al. Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults. Am J Hematol 2008, 83:524-527.
82. Brilakis E.S., Khera A., Saeed B., et al. Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. Clin Chem 2008, 54:1975-1981.
83. Kinney G.L., Snell-Bergeon J.K., Maahs D.M., et al. Lipoprotein-associated phospholipase A? Activity predicts progression of subclinical coronary atherosclerosis. Diabetes Technol Ther 2011, 13:381-387.
84. Koenig W., Vossen C.Y., Mallat Z., Brenner H., Benessiano J., Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 2009, 30:2742-2748.
85. Allison M.A., Denenberg J.O., Nelson J.J., Natarajan L., Criqui M.H. The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. J Vasc Surg 2007, 46:500-506.
86. Tselepis A.D., Panagiotakos D.B., Pitsavos C., Tellis C.C., Chrysohoou C., Stefanadis C. Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: the ATTICA Study. Atherosclerosis 2009, 206:303-308.
87. Paik J.K., Chae J.S., Jang Y., et al. Effects of V279F in the Lp-PLA(2) gene on markers of oxidative stress and inflammation in Koreans. Clin Chim Acta 2010, 411:486-493.
88. Anuurad E., Ozturk Z., Enkhmaa B., Pearson T.A., Berglund L. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab 2010, 95:2376-2383.
89. Gazi I., Lourida E.S., Filippatos T., Tsimihodimos V., Elisaf M., Tselepis A.D. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264-2273.
90. Lagos K.G., Filippatos T.D., Tsimihodimos V., et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 2009, 44:9-16.
91. Tsimihodimos V., Karabina S.A.P., Tambaki A.P., et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002, 43:256-263.
92. Milochevitch C., Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot Essent Fatty Acids 2001, 65:241-246.
93. Schaefer E., McNamara J., Asztalos B., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005, 95:1025-1032.
94. Noto H., Hara M., Karasawa K., et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:829-835.
95. Quarck R., De Geest B., Stengel D., et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001, 103:2495-2500.
96. Ishihara M., Iwasaki T., Nagano M., et al. Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients. J Hum Genet 2004, 49:302-307.
97. Jang Y., Waterworth D., Lee J.E., et al. Carriage of the V279F null allele within the gene encoding Lp-PLA? Is protective from coronary artery disease in South Korean males. PLoS One 2011, 6:e18208.
98. Wang Q., Hao Y., Mo X., et al. PLA2G7 gene polymorphisms and coronary heart disease risk: a meta-analysis. Thromb Res 2010, 126:498-503.
99. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002, 347:1916-1923.
100. Ferguson J.F., Hinkle C.C., Mehta N.N., et al. Translational studies of lipoprotein-associated phospholipase A? In inflammation and atherosclerosis. J Am Coll Cardiol 2012, 59:764-772.